Trials / Unknown
UnknownNCT04599426
Allogenic NK Cell Transfusion Azacitidine MDS-EB
Safety and Efficacy of Allogenic NK Cell Transfusion Combined With Azacitidine Therapy for the MDS-EB
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- The Second Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 15 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for refractory MDS-EB.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Allogeneic NK cell regimen group | 10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen. Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10\^6/kg d13，d15 . |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2023-12-30
- Completion
- 2023-12-30
- First posted
- 2020-10-22
- Last updated
- 2020-10-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04599426. Inclusion in this directory is not an endorsement.